🔗 Share this article Patients Stopping Slimming Injections Put On Pounds Four Times Faster Compared to Dieters Weight management involves long-term strategies. Fresh analysis indicates that individuals who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who end traditional diet and exercise programs. Research printed in a prominent medical journal shows that while overweight individuals can lose substantial amounts of their body weight while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month once they quit. "Users buying these treatments must be cognizant of the risk of fast weight regain when the therapy ends," stated researcher Dr. Susan Jebb. Such speed of regain implies a return to starting weight within about one and a half years. Analyzing Treatments The research, which reviewed 37 of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with conventional dieting. The team point out that people who shed pounds through lifestyle changes alone typically experience a more gradual weight regain—perhaps 0.1 kg a month—post-intervention. Explaining the Quick Rebound Nutrition scientists propose the mechanism of the drugs explains the accelerated regain. These medications mimic a natural hormone called GLP-1, which controls appetite. "Artificially providing the hormone concentrations far above than normal might result in the system to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist. "Discontinuation of this medication results in appetite is uncontrolled, making binge eating a significant risk." A Lifelong Disease? Health authorities recommend the injections for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes. Many experts argue that, considering the likelihood of weight regain, the therapy is often long-term. This opinion is supported by pharmaceutical companies, who say that the results "underscore the long-term nature of obesity," similar to managing diseases like high blood pressure. User Testimonies Users who have discontinued the medication describe a sudden resurgence of cravings. "I experienced a trigger activating and you become starving," recalled an individual. This challenge is compounded if individuals have not developed lasting lifestyle or habit changes during therapy. Widespread Adoption Survey data suggest that millions of adults in the UK have used these injections in the last 12 months, with demand remaining high. Adoption is more common among women compared to men. The 40s and 50s age group shows the greatest usage rates. Many obtain the drugs through private healthcare rather than public health services. Finally, experts stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a magic fix and maintained weight loss hinges on integrated behavioural support.
Weight management involves long-term strategies. Fresh analysis indicates that individuals who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who end traditional diet and exercise programs. Research printed in a prominent medical journal shows that while overweight individuals can lose substantial amounts of their body weight while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month once they quit. "Users buying these treatments must be cognizant of the risk of fast weight regain when the therapy ends," stated researcher Dr. Susan Jebb. Such speed of regain implies a return to starting weight within about one and a half years. Analyzing Treatments The research, which reviewed 37 of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with conventional dieting. The team point out that people who shed pounds through lifestyle changes alone typically experience a more gradual weight regain—perhaps 0.1 kg a month—post-intervention. Explaining the Quick Rebound Nutrition scientists propose the mechanism of the drugs explains the accelerated regain. These medications mimic a natural hormone called GLP-1, which controls appetite. "Artificially providing the hormone concentrations far above than normal might result in the system to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist. "Discontinuation of this medication results in appetite is uncontrolled, making binge eating a significant risk." A Lifelong Disease? Health authorities recommend the injections for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes. Many experts argue that, considering the likelihood of weight regain, the therapy is often long-term. This opinion is supported by pharmaceutical companies, who say that the results "underscore the long-term nature of obesity," similar to managing diseases like high blood pressure. User Testimonies Users who have discontinued the medication describe a sudden resurgence of cravings. "I experienced a trigger activating and you become starving," recalled an individual. This challenge is compounded if individuals have not developed lasting lifestyle or habit changes during therapy. Widespread Adoption Survey data suggest that millions of adults in the UK have used these injections in the last 12 months, with demand remaining high. Adoption is more common among women compared to men. The 40s and 50s age group shows the greatest usage rates. Many obtain the drugs through private healthcare rather than public health services. Finally, experts stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a magic fix and maintained weight loss hinges on integrated behavioural support.